The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| HOOK | -78.14% | -99.09% | -60.97% | -99% |
| S&P | +14.5% | +93.32% | +14.09% | +131% |
HOOKIPA Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in developing pharmaceutical products to prevent and cure infectious diseases and cancer. The firm also focuses on immunotherapeutics based on its proprietary arenavirus platform that is designed to reprogram the body’s immune system. The company was founded by Rolf M. Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel D. Pinschewer in 2011 and is headquartered in New York, NY.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $6.80M | 426.7% |
| Gross Profit | $6.33M | 999.1% |
| Gross Margin | 93.17% | 48.5% |
| Market Cap | $15.31M | -73.9% |
| Market Cap / Employee | $0.77M | 0.0% |
| Employees | 20 | 0.0% |
| Net Income | -$1.79M | 90.6% |
| EBITDA | -$6.21M | 71.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $34.34M | -55.5% |
| Accounts Receivable | $0.90M | 1001.2% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.30M | -91.2% |
| Short Term Debt | $0.25M | -83.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -63.01% | -32.3% |
| Return On Invested Capital | -67.74% | -10.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$7.13M | 50.5% |
| Operating Free Cash Flow | -$7.13M | 50.4% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.60 | 0.34 | 0.25 | 0.44 | -20.67% |
| Price to Sales | 1.08 | 0.55 | 1.45 | 1.07 | -24.68% |
| Price to Tangible Book Value | 0.60 | 0.34 | 0.25 | 0.44 | -20.67% |
| Enterprise Value to EBITDA | 0.18 | 0.89 | 1.51 | 2.88 | -3299.28% |
| Return on Equity | -52.0% | -61.7% | -105.8% | -97.6% | 99.25% |
| Total Debt | $2.83M | $0.88M | $0.60M | $0.55M | -88.85% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
